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but a proteolysis product having a strong tendency 
to precipitate at pH 8.0 [6], gave support to our 
previous hypothesis of a pathogenic role for the 
premature zymogen activation of over-stimulated 
acinar cells in pancreatitis [9, lo]. 
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1. P. ROUIMI, J. BONICEL AND 
M. ROVERY’S ANSWER 
First we would like to specify that our research 
group in the Centre de Biochimie et de Biologie 
Moleculaire, CNRS, Marseille, had nothing to do 
with the misunderstandings by several members of 
the same team which led to its breaking up in 198 1. 
In 1985, Professor H. Sarles and Dr A. De Caro 
asked us to collaborate in the determination of the 
primary structure of the human pancreatic stone 
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protein prepared from calculi (PSP) as well as of 
its immunoreactive forms from the pancreatic 
juice (PSP Sl-5). Our research group is indeed 
equipped for protein sequencing and trained in 
structural determination methods. Having worked 
for several years on pancreas proteolytic enzyme 
precursors, their activation, their proteolyses, the 
proposed research was of great interest to us and 
fitted into the frame of our research field. 
Together with Dr A. De Caro we endeavoured a 
thorough study of the various PSP forms. 
In the first report [l] written in collaboration, 
our contribution dealt with amino acid composi- 
tions and N-terminal sequence determinations of 
the 40 and 65 first amino acids of PSP and PSP Sl , 
respectively. At that time we mentioned the report 
of Dr Figarella’s group [2] since the 15 first amino 
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acids determined for ‘Protein X’ were identical to 
those of PSP and PSP Sl. No supplementary ex- 
periment on the PSP extracted from calculi was 
carried out, owing to the very small quantity of 
protein available. A year later we published the en- 
tire sequence of PSP Sl [3]. 
The immunoreactive proteins prepared by A. De 
Caro, PSP Sl and PSP S2-5 (14 kDa and 
16-19 kDa, respectively, evaluated by SDS-gel 
electrophoresis) have a common C-terminal group 
and a different N-terminal group (Ile for PSP Sl 
and a blocked end group for PSP S2-5). It was 
therefore obvious that a proteolysis in the N- 
terminal sequence of PSP S2-5 had transformed 
the protein into PSP Sl [4]. A peptide of PSP 
S2-5 peptic hydrolysate demonstrated that the 
cleaved bond was an Arg-Ile bond. The single N- 
terminal residue which appeared after a mild tryp- 
tic proteolysis of PSP S2-5 was Ile. SDS-gel elec- 
trophoresis showed that PSP S2-5 bands had 
practically disappeared to the advantage of a single 
band comparable to that of PSP Sl [4]. In con- 
trast, with chymotrypsin a weak proteolysis was 
obtained and several N-terminal residues appeared 
[41* 
We did not deem advisable to cite the article [2] 
in this matter since the authors had reported that 
a chymotryptic proteolysis was at the origin of the 
transformation. Since we knew that the split bond 
was actually an Arg-Ile bond, it was illogical to 
assume that the specific cleavage was due to the 
chymotrypsin. Two hypotheses may be put for- 
ward: (i) the cleaved bond in this work [2], was not 
an Arg-Ile bond but another close bond specifical- 
ly hydrolyzed by chymotrypsin. It would have been 
interesting to know the N-terminal residue(s) ap- 
pearing after this proteolysis. (ii) The chymotryp- 
sin preparation used was contaminated by trypsin. 
It is regrettable that the authors [2] had not studied 
the tryptic hydrolysis at the same time. 
2. A. DE CARO’S ANSWER 
We have studied several molecular forms of 
PSP. The form present in pancreatic stones, 
although obviously derived from the secretory 
form, is peculiar in several aspects: (i) it is 
associated with pathology; (ii) it has generally re- 
mained into calculi for a long time (several years); 
(iii) its study is difficult given the very small 
amount found in stones and the small amount of 
stones available. This is why, after the publication 
of the partial characterization of PSP [5], we 
decided to study the secretory forms of this pro- 
tein. Monoclonal antibodies against PSP were 
prepared in collaboration with Immunotech, and 
are now commercially available. Immunoabsor- 
bent columns allowed the fast purification of PSP 
S, and the further purification of PSP. The amino 
acid composition of highly purified PSP was dif- 
ferent from the first one. This remark has already 
been noted and published in the same paper [l] as 
the sequence of the first forty amino acids. The 
phosphate content of PSP is presently under 
reinvestigation. The presence of sugar in PSP was 
claimed on the basis of detection by the Schiff 
reagent only. A more thorough study is presently 
being carried out. 
Also, we recently described the presence of pro- 
teolyzed (unpublished) PSP in certain calculi [6], 
which could explain the presence of Asx N- 
terminal, as previously reported. 
In [7] we wrote this sentence “These results (ob- 
tained with mRNA) support the hypothesis that 
PSP is a molecular entity, and not a degradation 
product of trypsinogen 1 or another pancreatic 
protein”. We meant that PSP was a molecular en- 
tity and had no similarity with trypsinogen 1 or 
another already known pancreatic protein. 
From the beginning of our work, we disagreed 
with Dr Figarella’s hypothesis that PSP was not a 
new protein entity, but a degradation fragment of 
trypsinogen 1 [8]. We have shown that: (i) the 
samples of trypsin 1 used by Dr Figarella in her 
work were in fact contaminated by PSP [9]; (ii) us- 
ing two monoclonals against PSP (D4 and 2E7) no 
common epitope could be revealed between PSP 
and pure trypsin [9]; (iii) immunoprecipitation of 
human pancreatic mRNA translation products 
with antibodies against PSP and trypsin 1 gave 
distinct products [7]; (iv) the complete sequence of 
PSP S 1, one of the immunoreactive forms of PSP 
S, has been determined [3]. It shows no significant 
homology with the sequences of human trypsin 1 
and 2, as derived from the nucleotide sequence of 
their mRNA [lo]. 
In [2] the authors suggested that PSP could be 
derived from a precursor which could not be tryp- 
sinogen 1, but another protein immunologically 
related to trypsinogen 1. The above mentioned 
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